Home » Newsletters » BioWorld Science

BioWorld Science

March 25, 1999

View Archived Issues

Creative BioMolecules: year-end 1998 highlights

Genzyme Tissue Repair: Q4 1998 highlights

MethylGene initiates phase I clinical trials of MG-98 for solid tumors

Cellegy reacquires Glylorin rights from Glaxo Wellcome

Verelan PM launched for management of hypertension

Dainippon's AH-9700 is an excellent candidate for treatment of urge incontinence

Gastrointestinal effects and binding profile of Taisho's 5-HT4 agonist TS-951

Bristol-Myers Squibb announces Spanish launch of antiplatelet drug

Inhibitors of MCP-1 disclosed by Zeneca for inflammation

Novo Nordisk studies compounds that interact with KATP channels

CCK-A antagonist from Zeria shows promising activity in pancreatitis models

Potassium and/or chloride channel modulators claimed for incontinence and IBS

N-type Ca2+ blockers from Warner-Lambert for neurological disorders

Hokuriku Seiyaku discusses new agents for constipation at Japanese meeting

R.W. Johnson identifies mixed adrenergic agent with analgesic activity

NIP-142: a new-concept antiarrhythmic agent is presented by Nissan Chemical

Searle characterizes new vitronectin antagonist with antitumor activity at ACS meeting

Fujisawa presents COX-2 inhibitor with potent, morphine-like analgesic effects

Novel thrombin inhibitor series from 3-D discussed at ACS meeting

GTS-21 and donepezil exert synergistic cognition-enhancing effects in rats

Lack of efficacy for lanepitant in neuropathic pain

Kampo medicine demonstrates anxiolytic efficacy in mice

LY-334370: pharmacokinetics and safety during and outside a migraine attack

Suntory presents SUN-C5174, a 5-HT2 antagonist with potent antiplatelet activity

Intranasal dosing with BMS-181885 appears feasible, according to preliminary human data

U.S. patent issues for Genzyme's pseudo-adenoviral vectors

Alpha2-agonists in development at R.W. Johnson for use as analgesics

ACS highlights: progress with GABA-modulating neuroactive steroids at CoCensys

Nonbenzamidine factor Xa inhibitors in the pipeline at Rhone-Poulenc Rorer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...